Viewing Study NCT00439192

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 3:58 PM
Ignite Modification Date: 2026-05-14 @ 6:36 AM
Study NCT ID: NCT00439192
Status: TERMINATED
Last Update Posted: 2007-08-08
First Post: 2007-02-22
Is Gene Therapy: True
Has Adverse Events: False
Brief Title: ELB245 for 12 Weeks Versus 4mg Tolterodine in Patients With Incontinent Overactive Bladder (OAB)
Sponsor: elbion AG
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Overactive Bladder View
None Urinary Incontinence View
Keywords:

Keywords

Keyword Brief Keyword Text View
None OAB, proof of concept View
None Overactive Bladder (OAB) View
None with incontinence View